Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter‐2: Human midbrain dopamine neurons

The dopaminergic neurons in the ventral substantia nigra (SN) are significantly more vulnerable to degeneration in Parkinson's disease (PD) than the dopaminergic neurons in the ventral tegmental area (VTA). The ventral SN neurons also contain significantly more neuromelanin pigment than the dopaminergic neurons in the VTA. In vitro data indicate that neuromelanin pigment is formed from the excess cytosolic catecholamine that is not accumulated into synaptic vesicles by the vesicular monoamine transporter‐2 (VMAT2). By using quantitative immunohistochemical methods in human postmortem brain, we sought to examine the relative contents of VMAT2 within neurons that contain different amounts of neuromelanin pigment. The immunostaining intensity (ISI) was measured for VMAT2 and also for the rate‐limiting enzyme for the synthesis of dopamine, tyrosine hydroxylase (TH). ISI measures were taken from the ventral SN region where neurons are most vulnerable to degeneration in PD, nigrosome‐1 (N1); from the ventral SN region where cells are moderately vulnerable to degeneration in PD, the matrix (M); and from VTA neurons near the exit of the third nerve (subregion III). The data indicate that 1) subregion III neurons have significantly higher levels of VMAT2 ISI compared with N1 neurons (more than twofold) and M neurons (45%); 2) there is an inverse relationship between VMAT2 ISI and neuromelanin pigment in the N1 and III neurons; 3) there is an inverse relationship between VMAT2 ISI and the vulnerability to degeneration in PD in the N1, M, and III subregions; and 4) neurons with high VMAT2 ISI also have high TH ISI. These data support the hypothesis that midbrain dopaminergic neurons that synthesize greater amounts of dopamine have more vesicular storage capacity for action potential‐induced release of transmitter and that the ventral SN neurons accumulate the most neuromelanin pigment, in part because they have the least VMAT2 protein. J. Comp. Neurol. 473:97–106, 2004. © 2004 Wiley‐Liss, Inc.

[1]  B. Falkenburger,et al.  Dendrodendritic Inhibition Through Reversal of Dopamine Transport , 2001, Science.

[2]  D. German,et al.  The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter , 1998, Neuroscience.

[3]  David M. A. Mann,et al.  Possible role of neuromelanin in the pathogenesis of Parkinson's disease , 1983, Mechanisms of Ageing and Development.

[4]  N. Lindquist,et al.  Autoradiography of [14C]paraquat or [14C]diquat in frogs and mice: Accumulation in neuromelanin , 1988, Neuroscience Letters.

[5]  L. Greene,et al.  Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[6]  H. M. Swartz,et al.  The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: A hypothesis , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[7]  R. Roth,et al.  Extracellular dopamine and neurotensin in rat prefrontal cortex in vivo: effects of median forebrain bundle stimulation frequency, stimulation pattern, and dopamine autoreceptors , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[8]  A. Grace,et al.  The control of firing pattern in nigral dopamine neurons: burst firing , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[9]  D. Graham.  On the origin and significance of neuromelanin. , 1979, Archives of pathology & laboratory medicine.

[10]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[11]  O. H. Viveros,et al.  Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[12]  W. Nicklas,et al.  Studies on the Neurotoxicity of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine: Inhibition of NAD‐Linked Substrate Oxidation by Its Metabolite, 1‐Methyl‐4‐Phenylpyridinium , 1986, Journal of neurochemistry.

[13]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[14]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[15]  J. Glowinski,et al.  Dendritic release of dopamine in the substantia nigra , 1981, Nature.

[16]  G. Zeevalk,et al.  Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade. , 1995, The Journal of pharmacology and experimental therapeutics.

[17]  P. Lockhart,et al.  Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.

[18]  V. Pickel,et al.  Ultrastructural Localization of the Vesicular Monoamine Transporter-2 in Midbrain Dopaminergic Neurons: Potential Sites for Somatodendritic Storage and Release of Dopamine , 1996, The Journal of Neuroscience.

[19]  R. Swerdlow,et al.  Mitochondrial dysfunction in idiopathic Parkinson disease. , 1998, American journal of human genetics.

[20]  H Ujike,et al.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  E. Hirsch,et al.  Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine , 1995, Brain Research.

[22]  J. Haycock,et al.  Synaptic Vesicle Transporter Expression Regulates Vesicle Phenotype and Quantal Size , 2000, The Journal of Neuroscience.

[23]  R. Ellis,et al.  Macromolecular crowding: an important but neglected aspect of the intracellular environment. , 2001, Current opinion in structural biology.

[24]  P. Yates,et al.  The effects of ageing on the pigmented nerve cells of the human locus caeruleus and substantia nigra , 1979, Acta Neuropathologica.

[25]  S. Carmichael,et al.  Mechanisms of Toxicity and Cellular Resistance to 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine and 1‐Methyl‐4‐Phenylpyridinium in Adrenomedullary Chromaffin Cell Cultures , 1990, Journal of neurochemistry.

[26]  D. German,et al.  Electrophysiological and pharmacological evidence for the existence of distinct subpopulations of nigrostriatal dopaminergic neuron in the rat , 1988, Neuroscience.

[27]  A. Graybiel,et al.  The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. , 1999, Brain : a journal of neurology.

[28]  D. Radice,et al.  Iron and Other Metals in Neuromelanin, Substantia Nigra, and Putamen of Human Brain , 1994, Journal of neurochemistry.

[29]  R. Edwards,et al.  The role of vesicular transport proteins in synaptic transmission and neural degeneration. , 1997, Annual review of neuroscience.

[30]  D. German,et al.  Inhibition of striatal energy metabolism produces cell loss in the ipsilateral substantia nigra , 1997, Brain Research.

[31]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[32]  D. German,et al.  Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons , 2000, Neuroscience.

[33]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[34]  Wade K. Smith,et al.  Midbrain dopaminergic cell loss in parkinson's disease: Computer visualization , 1989, Annals of neurology.

[35]  D. Graham.  Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.

[36]  S. Snyder,et al.  Neuromelanin: a role in MPTP-induced neurotoxicity. , 1987, Life sciences.

[37]  G. Gessa,et al.  Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity , 1993, British journal of pharmacology.

[38]  P. Lansbury,et al.  Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? , 2002, Biochemistry.

[39]  Todd B. Sherer,et al.  Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.

[40]  R. Ellis,et al.  Macromolecular crowding: an important but neglected aspect of the intracellular environment. , 2001 .

[41]  S. Snyder,et al.  II. Neuromelanin: A role in MPTP-induced neurotoxicity , 1987 .

[42]  M. Sanghera,et al.  Low dopamine transporter mRNA levels in midbrain regions containing calbindin. , 1994, Neuroreport.

[43]  D. Kuhl,et al.  [3H]methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity , 1995, Neuroscience.

[44]  A. Levey,et al.  Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice , 1998, Journal of neurochemistry.

[45]  Kiowa S. Bower,et al.  Accelerated α‐synuclein fibrillation in crowded milieu , 2002 .

[46]  T. Shima,et al.  Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. , 1997, Free radical biology & medicine.